{"entity":{"id":"nct07283367","kind":"trial","name":"A Phase Ib/II Trial of HS-20110 Combination Therapies in Advanced Colorectal Cancer Patients.","aka":[],"tldr":"A phase 1/2 trial of Bevacizumab, Oxaliplatin and Capecitabine in colorectal cancer, run by Hansoh BioMedical R&D Company, now recruiting.","summary":"A Phase Ib/II Trial of HS-20110 Combination Therapies in Advanced Colorectal Cancer Patients. is a phase 1/2 interventional study registered as NCT07283367 by Hansoh BioMedical R&D Company, with 502 participants planned, started 2025-12-22 and due to reach its primary completion in 2029-12-31. Interventions recorded: Cohort 1: HS-20110+ Bevacizumab+5-FU/leucovorin, Cohort 2: HS-20110+Bevacizumab+Oxaliplatin+5-FU/leucovorin and Cohort 3: HS-20110+Bevacizumab+Oxaliplatin+Capecitabine.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07283367","url":"https://clinicaltrials.gov/study/NCT07283367"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["colorectal"],"sections":[],"technologies":[],"targets":[],"drugs":["bevacizumab","oxaliplatin","capecitabine"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07283367","phase":"1/2","setting":"A Phase Ib/II Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of HS-20110 Combination Therapies in Patients With Advanced Colorectal Cancer.","sponsor":"Hansoh BioMedical R&D Company","enrolled":502,"outcomes":[]},"route":"/trials/nct07283367/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"}],"drug":[{"id":"bevacizumab","kind":"drug","name":"Bevacizumab","route":"/drugs/bevacizumab/"},{"id":"capecitabine","kind":"drug","name":"Capecitabine","route":"/drugs/capecitabine/"},{"id":"oxaliplatin","kind":"drug","name":"Oxaliplatin","route":"/drugs/oxaliplatin/"}]}}